Tempo Bioscience Expands Patient-Relevant iPSC-Derived Cell Models

SAN FRANCISCO–(BUSINESS WIRE)–Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company
based in San Francisco, California, has released new human induced
pluripotent stem cell (iPSC) derived products and affiliated cell-based
services in the following categories:

These five new products add to the already-existing Tempo Bioscience
product line and expand TempoStemBank^™-iPSC offerings: 1)
neurons and glia in the central nervous system; 2) neurons in the
peripheral nervous system; 3) keratinocytes and melanocytes in the skin;
4) hepatocytes in the liver; and 5) retinal pigment epithelium cells in
the eye. TempoATP^™, TempoMito^™, and TempoVol^™
biosensors are live-cell reporters of cellular, mitochondrial, and
cytotoxicity functions.

Tempo Bioscience is the sole manufacturer of human iPSC-derived cell
models that are engineered using non-viral, nucleic-acids-free,
serum-free, and feeder-free technologies. Tempo is committed to
advancing technologies that focus on disease modeling and drug safety
evaluations using advanced human iPSC-derived cell models in 2D and 3D.
Tempo’s patient-relevant cell models aim to improve drug efficacy
evaluations and safety assessments during drug development.

The ultimate goal of Tempo Bioscience is to improve the drug development
process, utilizing advanced patient-relevant cell models and clinically
relevant computational modeling, to maximize efficiency, and to reduce
overall development cost.

About Tempo Bioscience, Inc.: Founded in 2013, Tempo is a technology
development biotechnology company based in San Francisco, California.
Tempo develops and manufactures human iPSC-based biosensor enabling
technologies for the biotech, pharmaceutical, and consumer product
industries. For more information on Tempo, please visit our home page: <http://www.tempobioscience.com>.
Follow us on LinkedIn, Twitter (@TempoBioscience) and TempoBlog.

Contacts

Tempo Bioscience, Inc
Angela L. Huang PhD
650-731-5620